Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387342488> ?p ?o ?g. }
- W4387342488 endingPage "2419" @default.
- W4387342488 startingPage "2419" @default.
- W4387342488 abstract "Diabetic retinopathy (DR) is a microvascular complication associated with vascular endothelial growth factor (VEGF) overexpression. Therapeutic delivery to the retina is a challenging phenomenon due to ocular biological barriers. Sorafenib tosylate (ST) is a lipophilic drug with low molecular weight, making it ineffective at bypassing the blood–retinal barrier (BRB) to reach the target site. Cubosomes are potential nanocarriers for encapsulating and releasing such drugs in a sustained manner. The present research aimed to compare the effects of sorafenib-tosylate-loaded cubosome nanocarriers (ST-CUBs) and a sorafenib tosylate suspension (ST-Suspension) via subconjunctival route in an experimental DR model. In this research, ST-CUBs were prepared using the melt dispersion emulsification technique. The distribution of prepared nanoparticles into the posterior eye segments was studied with confocal microscopy. The ST-CUBs were introduced into rats’ left eye via subconjunctival injection (SCJ) and compared with ST-Suspension to estimate the single-dose pharmacokinetic profile. Streptozotocin (STZ)-induced diabetic albino rats were treated with ST-CUBs and ST-Suspension through the SCJ route once a week for 28 days to measure the inhibitory effect of ST on the diabetic retina using histopathology and immunohistochemistry (IHC) examinations. Confocal microscopy and pharmacokinetic studies showed an improved concentration of ST from ST-CUBs in the retina. In the DR model, ST-CUB treatment using the SCJ route exhibited decreased expression levels of VEGF, pro-inflammatory cytokines, and adhesion molecules compared to ST-Suspension. From the noted research findings, it was concluded that the CUBs potentially enhanced the ST bioavailability. The study outcomes established that the developed nanocarriers were ideal for delivering the ST-CUBs via the SCJ route to target the retina for facilitated DR management." @default.
- W4387342488 created "2023-10-05" @default.
- W4387342488 creator A5019128564 @default.
- W4387342488 creator A5033326580 @default.
- W4387342488 creator A5035109980 @default.
- W4387342488 creator A5045103636 @default.
- W4387342488 creator A5055966957 @default.
- W4387342488 creator A5064678336 @default.
- W4387342488 creator A5064682051 @default.
- W4387342488 creator A5065120976 @default.
- W4387342488 creator A5082962154 @default.
- W4387342488 creator A5091048061 @default.
- W4387342488 date "2023-10-04" @default.
- W4387342488 modified "2023-10-11" @default.
- W4387342488 title "Subconjunctival Delivery of Sorafenib-Tosylate-Loaded Cubosomes for Facilitated Diabetic Retinopathy Treatment: Formulation Development, Evaluation, Pharmacokinetic and Pharmacodynamic (PKPD) Studies" @default.
- W4387342488 cites W1557326839 @default.
- W4387342488 cites W1815432645 @default.
- W4387342488 cites W1889509830 @default.
- W4387342488 cites W1923467661 @default.
- W4387342488 cites W1967957651 @default.
- W4387342488 cites W1998290564 @default.
- W4387342488 cites W2018516156 @default.
- W4387342488 cites W2047661114 @default.
- W4387342488 cites W2054620514 @default.
- W4387342488 cites W2067216473 @default.
- W4387342488 cites W2076619012 @default.
- W4387342488 cites W2078722368 @default.
- W4387342488 cites W2085260077 @default.
- W4387342488 cites W2095426581 @default.
- W4387342488 cites W2154204321 @default.
- W4387342488 cites W2155580843 @default.
- W4387342488 cites W2259225385 @default.
- W4387342488 cites W2291424433 @default.
- W4387342488 cites W2417039652 @default.
- W4387342488 cites W2891488942 @default.
- W4387342488 cites W2897157825 @default.
- W4387342488 cites W2907033774 @default.
- W4387342488 cites W2925338650 @default.
- W4387342488 cites W2940058582 @default.
- W4387342488 cites W3006534365 @default.
- W4387342488 cites W3010924828 @default.
- W4387342488 cites W3011522762 @default.
- W4387342488 cites W3014450877 @default.
- W4387342488 cites W3021977647 @default.
- W4387342488 cites W3030849293 @default.
- W4387342488 cites W3035134076 @default.
- W4387342488 cites W3087933272 @default.
- W4387342488 cites W3098441039 @default.
- W4387342488 cites W3129750893 @default.
- W4387342488 cites W3156844196 @default.
- W4387342488 cites W3160537228 @default.
- W4387342488 cites W3186062289 @default.
- W4387342488 cites W3213404732 @default.
- W4387342488 cites W4211205882 @default.
- W4387342488 cites W4254712757 @default.
- W4387342488 cites W4281550378 @default.
- W4387342488 cites W646651436 @default.
- W4387342488 doi "https://doi.org/10.3390/pharmaceutics15102419" @default.
- W4387342488 hasPublicationYear "2023" @default.
- W4387342488 type Work @default.
- W4387342488 citedByCount "0" @default.
- W4387342488 crossrefType "journal-article" @default.
- W4387342488 hasAuthorship W4387342488A5019128564 @default.
- W4387342488 hasAuthorship W4387342488A5033326580 @default.
- W4387342488 hasAuthorship W4387342488A5035109980 @default.
- W4387342488 hasAuthorship W4387342488A5045103636 @default.
- W4387342488 hasAuthorship W4387342488A5055966957 @default.
- W4387342488 hasAuthorship W4387342488A5064678336 @default.
- W4387342488 hasAuthorship W4387342488A5064682051 @default.
- W4387342488 hasAuthorship W4387342488A5065120976 @default.
- W4387342488 hasAuthorship W4387342488A5082962154 @default.
- W4387342488 hasAuthorship W4387342488A5091048061 @default.
- W4387342488 hasBestOaLocation W43873424881 @default.
- W4387342488 hasConcept C111113717 @default.
- W4387342488 hasConcept C112705442 @default.
- W4387342488 hasConcept C118487528 @default.
- W4387342488 hasConcept C126322002 @default.
- W4387342488 hasConcept C134018914 @default.
- W4387342488 hasConcept C142724271 @default.
- W4387342488 hasConcept C178790620 @default.
- W4387342488 hasConcept C181389837 @default.
- W4387342488 hasConcept C18150654 @default.
- W4387342488 hasConcept C185592680 @default.
- W4387342488 hasConcept C2778019345 @default.
- W4387342488 hasConcept C2778695046 @default.
- W4387342488 hasConcept C2779540182 @default.
- W4387342488 hasConcept C2779742858 @default.
- W4387342488 hasConcept C2779820397 @default.
- W4387342488 hasConcept C2779829184 @default.
- W4387342488 hasConcept C2780035454 @default.
- W4387342488 hasConcept C2780827179 @default.
- W4387342488 hasConcept C555293320 @default.
- W4387342488 hasConcept C71924100 @default.
- W4387342488 hasConcept C98274493 @default.
- W4387342488 hasConceptScore W4387342488C111113717 @default.
- W4387342488 hasConceptScore W4387342488C112705442 @default.
- W4387342488 hasConceptScore W4387342488C118487528 @default.
- W4387342488 hasConceptScore W4387342488C126322002 @default.